Anti-Human CXCR4 Reference Antibody (PF-06747143, RUO) (HX206096)

Name: Anti-Human CXCR4 Reference Antibody (PF-06747143, RUO)
Brand: abinScience
SKU: HX206096
Price: 370 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HX206096
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG
Clone ID	PF-06747143
Biological activity	PF-06747143 (20 ug/mL) binds specifically to human CXCR4-expressing CHO-hCXCR4 cells, with no binding to CXCR4-negative CHO-parental cells [1]. PF-06747143 (110 min) potently inhibits CXCL12-induced calcium flux in Jurkat cells with an IC 50 of 1.41 nM, and this inhibitory activity does not require antibody bivalency or the Fc region [1]. PF-06747143 (10-1000 nM; 48 h) induces bivalency-dependent cell death in patient-derived primary CLL-B cells, with activity independent of stromal cell support, CLL prognostic risk factors, or TP53 status, and minimal effect on normal B and T lymphocytes [1]. PF-06747143 (100 nM; 48 h) induces caspase-independent cell death in patient-derived primary CLL-B cells [1]. PF-06747143 (100 nM) induces bivalency-dependent ROS production and subsequent cell death in patient-derived primary CLL-B cells, with ROS levels comparable to the programmed cell death-inducing antibody obinutuzumab [1]. PF-06747143 (10-1000 nM) potently inhibits CXCL12-induced F-actin polymerization in primary CLL-B cells, with 100 and 1000 nM reducing polymerization below baseline levels [1]. PF-06747143 (10 nM-1 uM; 1 h pre-incubation) dose-dependently inhibits CXCL12-induced migration of primary CLL-B cells [1]. PF-06747143 (0.2-2000 nM; 4 h) induces dose-dependent complement-dependent cytotoxicity in primary CLL-B cells, with significantly greater activity in the presence of active complement [1]. PF-06747143 induces potent antibody-dependent cell-mediated cytotoxicity in primary CLL-B cells and JVM-13 CLL tumor cells, with activity dependent on the IgG1 Fc region [1]. PF-06747143 significantly inhibits CXCL12-induced chemotaxis in primary AML cells [2]. PF-06747143 (65 nM; 4-5 h) potently inhibits CXCL12-driven migration of HL-60, U937, and primary AML cells [3]. PF-06747143 (0-100 nM; 4 h) induces dose-dependent ADCC-mediated cytotoxicity in primary AML BM cells and MV4-11 cells via Fc-effector function, with activity dependent on CXCR4 expression [3].
Expression system	Mammalian cells
Clonality	Monoclonal
Target	Stromal cell-derived factor 1 receptor, LCR1, HM89, LPS-associated protein 3, LAP-3, CXC-R4, CXCR-4, SDF-1 receptor, CD184, NPYRL, LESTR, Fusin, FB22, C-X-C chemokine receptor type 4, CXCR4, Lipopolysaccharide-associated protein 3, Leukocyte-derived seven transmembrane domain receptor
Endotoxin level	< 10 EU/mg
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P61073
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	PF-06747143, PF06747143, PF06747143
Background	C-X-C chemokine receptor type 4 (CD184/CXCR4) is a ~39 kDa protein. Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. CXCR4 is coupled to G(i) G alpha proteins and mediates inhibition of adenylate cyclase. Involved in the AKT signaling cascade. Plays a role in regulation of cell migration, e.g. 1. Brelot, A. et al. (1999) Journal of virology 73, 2576-86. PMID: 10074102 2. Gupta, SK. et al. (1999) Journal of immunology (Baltimore, Md. : 1950) 163, 2368-72. PMID: 10452968 3. Cheng, ZJ. et al. (2000) The Journal of biological chemistry 275, 2479-85. PMID: 10644702 4. Brelot, A. et al. (2000) The Journal of biological chemistry 275, 23736-44. PMID: 10825158 5. Veldkamp, CT. et al. (2008) Science signaling 1, ra4. PMID: 18799424 6. Busillo, JM. et al. (2010) The Journal of biological chemistry 285, 7805-17. PMID: 20048153 7. Malik, R. et al. (2010) Molecular biology of the cell 21, 2529-41. PMID: 20505072 8. Cao, Y. et al. (2015) Leukemia 29, 169-76. PMID: 24912431 9. Lear, T. et al. (2017) American journal of physiology. Cell physiology 313, C584-C592. PMID: 28978524 10. Bleul, CC. et al. (1996) Nature 382, 829-33. PMID: 8752280
References	1. Kashyap MK, et al. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. J Hematol Oncol. 2017;10(1):112. Published 2017 May 19. [HX206096] 2. Zhang Y, et al. Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143). Sci Rep. 2017 Aug 4;7(1):7305. [HX206096] 3. Zhang Y, et al. Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143). Sci Rep. 2017;7(1):7305. Published 2017 Aug 4. [HX206096] 4. Liu SH, et al. A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies. Blood Adv. 2017;1(15):1088-1100. Published 2017 Jun 21. View More [HX206096]
Note	For research use only. Not suitable for clinical or therapeutic use.